A Levo Therapeutics drug designed to curb the insatiable hunger experienced by patients with Prader-Willi syndrome has fallen short at the FDA, as the regulator turned down the biotech’s drug ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Acadia Pharmaceuticals is giving up on a drug to treat ...

REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I respect the investigative skills and short ...

Q3 2025 Management View CEO Sergio Traversa highlighted a "standout year" for Relmada, citing "excellent product development ...

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia ...

The "Biosimilar Growth Hormones Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com’s offering. Major players in the biosimilar growth hormone ...

An investigational carbetocin nasal spray for treating extreme hunger and other symptoms of Prader-Willi syndrome (PWS), a rare genetic disorder, received a near-unanimous thumbs-down from FDA ...

PENNSAUKEN — A local teenager has died after a life-long battle against a rare disorder. Alexander Tran, 17, was looking forward to graduation next year from Pennsauken High School student, his family ...

REDWOOD CITY, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...